The antibacterial activities of drugs were determined by a two-fold agar dilution method mainly using MuellerHinton agar (Eiken Chemical Co., Tokyo, Japan). Heart infusion agar (Nissui Seiyaku Co., Tokyo, Japan) with 5%
Introduction
Imipenem was the first carbapenem antibiotic to be put to clinical use. Although it has broad-spectrum antibacterial activity against pathogens including Pseudomonas aeruginosa and Enterococcus faecalis, it is hydrolysed by dehydropeptidase-1 (DHP-1) in renal tissue. 1 Therefore, cilastatin, a DHP-1 inhibitor, must be combined with imipenem to prevent the degradation of the antibiotic.
BO-2727 is a new injectable carbapenem carrying an (R)-1-hydroxymethyl-methylaminopropyl group ( Figure  1 ). The stability of BO-2727 in the presence of DHP-1 is much greater than that of imipenem, slightly greater than that of meropenem and almost equivalent to that of biapenem. 2 Therefore, BO-2727 can be used without a DHP-I inhibitor. In this study, we compared the in-vitro and in-vivo biological properties of BO-2727 with those of meropenem, imipenem and biapenem. We also further investigated the mechanism of action of BO-2727 by studying morphological changes in bacteria and affinities for penicillin-binding proteins (PBPs). This work was presented in part at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 3 Figure 1 shows the structures of the antimicrobial agents used in this study. BO-2727, imipenem, cilastatin and methicillin were from Banyu Pharmaceutical Co., Ltd (Tokyo, Japan), meropenem from Sumitomo Pharmaceutical Co., Ltd (Osaka, Japan) and biapenem from Lederle Japan (Tokyo, Japan).
Materials and methods

Antimicrobial agents
Bacterial strains
The bacteria used in this study were our laboratory strains and clinical isolates; a total of 994 clinical isolates obtained from several hospitals in Japan. All of the strains were stored in the Department of Microbiology, Kyoto Pharmaceutical University, Kyoto, Japan. defibrinated horse blood was used for streptococci and Moraxella catarrhalis, and 3% Fildes' enrichment (Difco Laboratories, Detroit, MI, USA) for Haemophilus influenzae. Chocolate agar was used for Neisseria gonorrhoeae. The overnight broth cultures and bacterial suspensions were diluted in fresh broth to a final concentration of approximately 10 6 cfu/mL, and a loopful (5 L) of each bacterial suspension was applied on to plates with a Microplanter (Sakuma Seisakusho, Tokyo, Japan). All aerobes were incubated at 37°C for 18 h. N. gonorrhoeae was incubated for 48 h in a candle chamber.
Time-kill study
The bactericidal activities of BO-2727 and imipenem against Staphylococcus aureus 209P JC, Escherichia coli K-12 and P. aeruginosa PAO1 were determined. An overnight culture in Mueller-Hinton broth was diluted with fresh broth and incubated at 37°C with shaking for 2 h. BO-2727 was added to a final concentration of 0.25-4 MIC when the density of the culture reached about 10 6 cfu/mL. After incubation for 1, 2 and 4 h at 37°C with shaking, an aliquot of the culture was withdrawn and serially diluted. A portion (0.1 mL) of the diluent was plated on Mueller-Hinton agar and incubated at 37°C for 18 h, after which the viable cells were counted.
Morphological observation
Overnight cultures of E. coli K-12 and P. aeruginosa PAO1 were diluted to 10 6 cfu/mL in Mueller-Hinton broth and incubated for 2 h at 37°C with shaking. A loopful of bacterial suspension was seeded on to heart infusion agar on glass slides containing different concentrations of BO-2727, meropenem, imipenem and biapenem. After the glass slides had been incubated at 37°C for 3 h, morphological changes in the cells were observed by phasecontrast microscopy.
Affinity for PBPs
The affinities of BO-2727 and imipenem for the PBPs of E. coli K-12 and P. aeruginosa PAO1 were determined as described by Spratt, 4 with some modifications. 5, 6 The concentration of each drug that inhibited the subsequent binding of [ 14 C]benzylpenicillin (Amersham Japan, Tokyo, Japan) to each PBP by 50% (IC 50 ) was determined by scanning the fluorograms with a densitometer (Atto, Tokyo, Japan).
In-vivo efficacy
In-vivo efficacy was examined via systemic infections in mice. Male ddY mice (4 weeks old) were infected intraperitoneally with bacteria suspended in 5% gastric mucin. The mice were treated subcutaneously with a single dose of each test compound 2 h after infection. The 50% effective doses (ED 50 s) were calculated from the number of survivors on day 7 after infection by the LitchfieldWilcoxon method. 
Results
In-vitro activity of BO-2727
The antibacterial activity of BO-2727 was determined for 994 clinical isolates and compared with that of meropenem, imipenem and biapenem (Table I) . BO-2727 showed broad-spectrum activity against pathogens including 6 .25 mg/L) and enterococci were slightly inferior to those of imipenem but superior to those of meropenem and biapenem. BO-2727 was four-to eight-fold more active against methicillin-resistant S. aureus (MICs of methicillin 12.5 mg/L) than were the other carbapenems, inhibiting all isolates at 12.5 mg/L. BO-2727 was also the most active carbapenem against Staphylococcus epidermidis. BO-2727 inhibited all isolates of Streptococcus pneumoniae and Streptococcus pyogenes at 0.012 mg/L and 0.006 mg/L, respectively. Against Gram-negative bacteria except S. marcescens and P. aeruginosa, meropenem was the most active agent, and the activity of BO-2727 was similar to that of imipenem and biapenem. The MIC 90 s of BO-2727, meropenem and biapenem against Serratia marcescens were all 6.25 mg/L, while that of imipenem was 1.56 mg/L. BO-2727 was two-to four-fold more active against imipenem-susceptible, imipenem-resistant and ofloxacinresistant P. aeruginosa than were the other carbapenems. Figure 2 shows the killing kinetics of BO-2727 against S. aureus, E. coli and P. aeruginosa. With respect to S. aureus and P. aeruginosa, rapid killing was observed at 1, 2 and 4 MIC, while against E. coli, the bactericidal activity of BO-2727 was comparatively moderate at 1, 2 and 4 MIC. Figure 3 shows the morphological changes in E. coli. BO-2727 induced formation of spherical forms at a concentration of 0.05 mg/L, which corresponds to its MIC. Significant bubble formation was also observed in most of the cells at a concentration of 0.1 mg/L (Figure 3d and e). Imipenem induced similar morphological changes and caused cell lysis without bubble formation at 2 MIC (Figure 2h ). Figure 4 shows the morphological changes in P. aeruginosa. BO-2727 induced dose-dependent bulge formation and subsequent cell lysis (Figure 4b-e) . In contrast, imipenem induced swollen or lysed cells at the MIC (Figure 4h ). Table II shows the IC 50 s of BO-2727 and imipenem for the PBPs of E. coli and P. aeruginosa. BO-2727 and imipenem had remarkably high affinities for PBP 2 of E. coli. Against the PBPs of P. aeruginosa, BO-2727 showed highest affinity for PBP 4 and then for PBP 2 and PBP 3. Imipenem primarily bound to PBP 4 and to a lesser extent to PBP 2, PBP 1A and 1B. Imipenem had a higher affinity for the PBP 5 of both species than BO-2727.
Bactericidal activity
Morphological observation
Affinity for PBPs
In-vivo efficacy
The therapeutic efficacy of BO-2727 in mice is shown in Table III . BO-2727 was ten-fold less effective than imipenem against S. pneumoniae infection, three-fold more effective against S. pyogenes infection and equally effective against infections with other organisms. The protective effects of BO-2727 were slightly less than those of biapenem for most species but were superior in infection with P. aeruginosa KYB-1. BO-2727 was more effective than meropenem, except in infections with Enterobacteriaceae. 
Discussion
The results of this study indicate that BO-2727 has broadspectrum antibactericidal activity against both Grampositive and Gram-negative bacteria. In particular, BO-2727 was more potent against methicillin-resistant S. aureus (MRSA) and P. aeruginosa, including imipenemor quinolone-resistant isolates, than were the other tested carbapenems such as meropenem, imipenem and biapenem. These results correspond well with previous reports.
2,8 BO-2727 was reported to have a high affinity for the PBP 2 of MRSA. 9 BO-2727 was also found to be highly 10 These characteristics suggest superior activity of BO-2727 against methicillin-resistant S. aureus and P. aeruginosa. BO-2727 showed dose-dependent bactericidal activity against S. aureus, E. coli and P. aeruginosa.
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Morphologically, the cell swelling caused by BO-2727 in E. coli may be attributable to high affinity for PBP 2. Similar morphological changes were observed with imipenem. Bulge formation caused by BO-2727 in P. aeruginosa may be attributable to relatively higher affinity for PBP 2 and PBP 3, compared with that for PBP 1A. In contrast, imipenem instantly induced cell lysis because of higher affinity for PBP 1A, 1B and 2 than for PBP 3. Biapenem induced similar morphological changes to BO-2727 in both strains because of its comparable PBP-binding patterns. 11 Meropenem has higher affinities for the PBP 3 of both species and produced different morphological changes than other carbapenems. 12 Inhibition of PBP 4 and PBP 5 has little effect on bactericidal activity because they are not essential in E. coli, 13 the PBP 4 and PBP 5 of P. aeruginosa are similar. 6 BO-2727 showed good prophylactic efficacy in mouse systemic infections caused by Gram-positive and Gramnegative bacteria. The therapeutic potency of BO-2727 was similar to that of imipenem/cilastatin and biapenem. These results correspond with our in-vitro data.
In conclusion, BO-2727 has good in-vitro and in-vivo activity. Our findings suggest that the antibacterial activity of carbapenem antibiotics could be expanded to encompass MRSA and imipenem-resistant P. aeruginosa. This drug was effective in phase II clinical trials, but a high incidence of liver function abnormality was observed. Therefore further development of this drug will be difficult. 
